X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare STRIDES PHARMA SCIENCE with - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs ALKEM LABORATORIES - Comparison Results

STRIDES PHARMA SCIENCE    Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE ALKEM LABORATORIES STRIDES PHARMA SCIENCE/
ALKEM LABORATORIES
 
P/E (TTM) x 51.1 - - View Chart
P/BV x 1.1 6.6 16.9% View Chart
Dividend Yield % 0.4 0.7 66.2%  

Financials

 STRIDES PHARMA SCIENCE   ALKEM LABORATORIES
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
ALKEM LABORATORIES
Mar-16
STRIDES PHARMA SCIENCE/
ALKEM LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1,1471,589 72.2%   
Low Rs6421,232 52.1%   
Sales per share (Unadj.) Rs317.2417.5 76.0%  
Earnings per share (Unadj.) Rs7.856.3 13.9%  
Cash flow per share (Unadj.) Rs25.164.7 38.7%  
Dividends per share (Unadj.) Rs2.0012.70 15.7%  
Dividend yield (eoy) %0.20.9 24.8%  
Book value per share (Unadj.) Rs274.3292.9 93.6%  
Shares outstanding (eoy) m89.50119.57 74.9%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.83.4 83.4%   
Avg P/E ratio x114.025.1 455.1%  
P/CF ratio (eoy) x35.721.8 163.8%  
Price / Book Value ratio x3.34.8 67.7%  
Dividend payout %25.522.6 113.0%   
Avg Mkt Cap Rs m80,058168,653 47.5%   
No. of employees `0002.5NA-   
Total wages/salary Rs m4,3419,171 47.3%   
Avg. sales/employee Rs Th11,325.8NM-  
Avg. wages/employee Rs Th1,731.4NM-  
Avg. net profit/employee Rs Th280.1NM-  
INCOME DATA
Net Sales Rs m28,39449,915 56.9%  
Other income Rs m9411,645 57.2%   
Total revenues Rs m29,33451,561 56.9%   
Gross profit Rs m3,9658,482 46.7%  
Depreciation Rs m1,5401,006 153.2%   
Interest Rs m1,962671 292.6%   
Profit before tax Rs m1,4038,451 16.6%   
Minority Interest Rs m0-114 0.0%   
Prior Period Items Rs m-1680-   
Extraordinary Inc (Exp) Rs m-4360-   
Tax Rs m971,606 6.1%   
Profit after tax Rs m7026,731 10.4%  
Gross profit margin %14.017.0 82.2%  
Effective tax rate %6.919.0 36.5%   
Net profit margin %2.513.5 18.3%  
BALANCE SHEET DATA
Current assets Rs m24,83627,062 91.8%   
Current liabilities Rs m18,99315,324 123.9%   
Net working cap to sales %20.623.5 87.5%  
Current ratio x1.31.8 74.0%  
Inventory Days Days7167 106.7%  
Debtors Days Days11341 274.7%  
Net fixed assets Rs m34,28912,610 271.9%   
Share capital Rs m895239 374.3%   
"Free" reserves Rs m23,65134,490 68.6%   
Net worth Rs m24,54635,027 70.1%   
Long term debt Rs m15,5131,212 1,280.4%   
Total assets Rs m65,43754,387 120.3%  
Interest coverage x1.713.6 12.6%   
Debt to equity ratio x0.60 1,827.1%  
Sales to assets ratio x0.40.9 47.3%   
Return on assets %4.113.6 29.9%  
Return on equity %2.919.2 14.9%  
Return on capital %6.924.9 27.7%  
Exports to sales %012.9 0.0%   
Imports to sales %03.1 0.0%   
Exports (fob) Rs mNA6,461 0.0%   
Imports (cif) Rs mNA1,540 0.0%   
Fx inflow Rs m15,6976,563 239.2%   
Fx outflow Rs m7353,012 24.4%   
Net fx Rs m14,9623,552 421.3%   
CASH FLOW
From Operations Rs m1,8717,259 25.8%  
From Investments Rs m5,8261,864 312.5%  
From Financial Activity Rs m-10,157-9,273 109.5%  
Net Cashflow Rs m-2,615-150 1,743.3%  

Share Holding

Indian Promoters % 27.7 66.9 41.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 37.8 33.1 114.2%  
FIIs % 8.6 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 0.0 -  
Shareholders   56,241 68,381 82.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   DR. DATSONS LABS  DISHMAN PHARMA  TTK HEALTHCARE  ASTRAZENECA PHARMA  DIVIS LABORATORIES  

Compare STRIDES PHARMA SCIENCE With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 190 Points Higher; Consumer Durable and Healthcare Stocks Witness Buying(Closing)

After trimming sharp losses in the afternoon session, Indian share markets continued to witness buying interest and ended the day on a positive note.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY19); Net Profit Down 72.2% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 54 m (down 72.2% YoY). Sales on the other hand came in at Rs 7 bn (down 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES SHASUN LTD 2017-18 Annual Report Analysis (Annual Result Update)

Oct 1, 2018 | Updated on Oct 1, 2018

Here's an analysis of the annual report of STRIDES SHASUN LTD for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of STRIDES SHASUN LTD. Also includes updates on the valuation of STRIDES SHASUN LTD.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


Dec 11, 2018 (Close)

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE - MERCK LTD COMPARISON

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS